Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr-Jun;9(2):2045894019846433.
doi: 10.1177/2045894019846433.

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

Pilar Escribano-Subias  1 , Hakim Bendjenana  2 , Paula S Curtis  3 , Irene Lang  4 , Anton Vonk Noordegraaf  5
Affiliations

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

Pilar Escribano-Subias et al. Pulm Circ. 2019 Apr-Jun.

Abstract

This multicenter, randomized, double-blind, placebo-controlled study assessed ambrisentan or placebo in patients with inoperable chronic thromboembolic pulmonary hypertension. Futility of enrollment led to early termination. Trends of improvement in favor of ambrisentan versus placebo in the primary and some secondary endpoints were observed; adverse event profiles were similar between groups.

Keywords: 6MWD; AMBER 1; Group 4 pulmonary hypertension; Six-minute walk distance.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Change from baseline over 16 weeks in (a) 6MWD and (b) NT-proBNP in the double-blind study (observed case data, ITT population). Error bars represent 95% CI values. For NT-proBNP, values shown are the percent change in the geometric mean ratio of week 16 to baseline. 6MWD, 6-min walk distance; CI, confidence interval; ITT, intent-to-treat; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
See this image and copyright information in PMC

References

    1. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation 2014; 130: 508–518. - PubMed
    1. Hoeper MM, Madani MM, Nakanishi N, et al. Chronic thromboembolic pulmonary hypertension. Lancet Respir Med 2014; 2: 573–582. - PubMed
    1. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003; 76: 1457–1462. discussion 62–64. - PubMed
    1. Gilead Sciences Inc. Letairis prescribing information. Available at: https://www.gilead.com/-/media/files/pdfs/medicines/cardiovascular/letai... (accessed April 2019).
    1. Reesink HJ, Meijer RC, Lutter R, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J 2006; 70: 1058–1063. - PubMed

LinkOut - more resources